Antimicrobial resistance and sepsis are inherently interconnected issues, but are campaigns for antibiotic stewardship competing against sepsis awareness campaigns with regards to their messages on antibiotic use?
A study presented at ECCMID has suggested patient outcomes for Gram-negative bacteremia are similar in the case of 7 days and 14 days of antibiotic treatment, suggesting a shorter course length could be beneficial.
Could carbon monoxide be used to manage sepsis-related lung injury? – an interview with Bryan Kraft, MD
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
A small clinical trial has demonstrated that an IL-7 drug that revs up the body’s immune system holds promise in sepsis patients, potentially offering a new approach to improve survival rates.
A new study has revealed that serum IgA antibodies deliver a protective barrier against polymicrobial sepsis in mice, providing us with a further understanding of its role in host protection.
While sepsis is well defined clinically, the molecular immunological mechanisms that underlie the development of sepsis are poorly understood.